ArticleTropical medicine and health2021
Emergence of cutaneous leishmaniasis in Nepal.
Article in Tropical medicine and health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Effectiveness of Long-lasting Insecticide-Impregnated Bed Nets in Controlling Phlebotomus argentipes in Sri Lanka: A Cluster Randomized Controlled Trial.The Journal of infectious diseases · 2025Trial
- Isolated mucosal leishmaniasis: A rare presentation from an endemic region of Nepal.JAAD case reports · 2026Article
- Incidence and clinical patterns of cutaneous leishmaniasis at a Tertiary hospital in Hadiya Zone, Ethiopia: a hospital-based cross-sectional study.BMC infectious diseases · 2026Article
- Cutaneous Leishmaniasis in High-Altitude: A Case Report From Nepal.Clinical case reports · 2026Article
- Laryngeal leishmaniasis presenting with hoarseness in a child from the highland of Nepal: A rare diagnostic challenge.IDCases · 2026Article
- Mapping the distribution of phlebotomine sand fly species with emphasis on Leishmania vectors in Nepal and exploring the potential of DNA barcoding for their identification.Scientific reports · 2025Article
- Can cutaneous leishmaniasis provoke a resurgence of kala-azar in the Indian subcontinent?BMC infectious diseases · 2025Article
- Salivary antigens rPagSP02 and rPagSP06 are a reliable composite biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka.Scientific reports · 2024Article
- rPagSP02+rPagSP06 recombinant salivary antigen is a reliable biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka.Research square · 2024Article
- Source Tracing of Leishmania donovani in Emerging Foci of Visceral Leishmaniasis, Western Nepal.Emerging infectious diseases · 2024Article
- Leishmania donovani persistence and circulation causing cutaneous leishmaniasis in unusual-foci of Nepal.Scientific reports · 2023Article
- Intracellular amastigotes in fine-needle aspiration cytology of cutaneous leishmaniasis.Clinical case reports · 2023Article
- A rare case of cutaneous leishmaniasis in Kathmandu presenting with features of bacterial skin infection: A case report.Clinical case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous leishmaniasis (CL) is endemic in 70 countries worldwide. Nepal is considered non-endemic for CL and hence the control program is targeted to visceral leishmaniasis (VL) only. Here, we report the emergence of CL cases in different parts of Nepal.
methodsWe analyzed the CL and VL cases reported to Epidemiology and Diseases Control Division (EDCD), Ministry of Health and Population, Nepal through District Health Information System 2 (DHIS-2) and Early Warning and Reporting System (EWRS) during the past 4 years (2016-2019). Any laboratory-confirmed case was included in the study. Demographic and clinical details of each patient were transcribed into Excel sheets, verified with the case report forms and analyzed.
resultsVL has been reported in Nepal since 1980, but CL was reported very recently. From 2016 to 2019, 42 CL cases were reported from 26 different hospitals to EDCD which had been diagnosed on the basis of clinical presentation, and laboratory findings (demonstration of amastigotes in Giemsa-stained smears and rK39 test results). Majority of the patients (31.0%, 13/42) visited to the hospital within 1-6 months of onset of lesions. Facial region (38.1%, 16/42) was the common place where lesions were found ompared to other exposed parts of the body. CL was successfully treated with miltefosine for 28 days. The majority of CL patients did not have history of travel outside the endemic areas and there was no report of sandfly from these areas.
conclusionThese evidences highlight that the Government of Nepal need to pay more efforts on CL and include it in differential diagnosis by clinicians, and plan for an active surveillance when the country is targeting leishmaniasis elimination by the year 2025 with the decreasing number of VL cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.